- Home
- BLKB vs RARE Comparison
BLKB vs RARE Comparison
Compare BLKB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | RARE |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BLKB | RARE |
|---|---|---|
| Price | $63.51 | $36.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $70.50 | ★ $85.20 |
| AVG Volume (30 Days) | 343.2K | ★ 1.2M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,136,093,000.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | $4.09 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $54.56 | $25.81 |
| 52 Week High | $83.20 | $50.00 |
Technical Indicators
Market Signals| Indicator | BLKB | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 62.08 |
| Support Level | $55.88 | $33.16 |
| Resistance Level | $58.00 | $34.77 |
| Average True Range (ATR) | 1.87 | 1.52 |
| MACD | 0.94 | 0.36 |
| Stochastic Oscillator | 86.90 | 83.52 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.